{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:36:15Z","timestamp":1759336575173,"version":"build-2065373602"},"reference-count":5,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>We present two case reports with resolution of PCT following treatment with direct-acting anti-virals for hepatitis C infection (HCV): An 82-year-old woman and a 60-year-old woman with PCT caused by HCV. Both patients were treated with venesection and hydroxychloroquine for their PCT. The patients received treatment with glecaprevir\/pibrentasvir, resulting in the eradication of HCV and long-term remission of PCT. The cases illustrate the importance of screening patients with PCT for underlying HCV, and initiating relevant treatment for HCV, as this may lead to remission in PCT.<\/jats:p>","DOI":"10.61409\/v01250056","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T10:36:11Z","timestamp":1758105371000},"page":"1-4","source":"Crossref","is-referenced-by-count":0,"title":["Porphyria cutanea tarda and hepatitis C infection"],"prefix":"10.61409","author":[{"given":"Anne","family":"Stockmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Lindegaard","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik Frank","family":"Lorentzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Christiansen AL, Aagaard L, Krag A et al. Cutaneous porphyrias: causes, symptoms, treatments and the Danish incidence 1989-2013. Acta Derm Venereol. 2016;96(7):868-872. https:\/\/doi.org\/10.2340\/00015555-2444","DOI":"10.2340\/00015555-2444"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Thomadakis C, Gountas I, Duffell E et al. Prevalence of chronic HCV infection in EU\/EEA countries in 2019 using multiparameter evidence synthesis. Lancet Reg Health Eur. 2023;36:100792. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100792","DOI":"10.1016\/j.lanepe.2023.100792"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Bonkovsky HL, Rudnick SR, Ma CD et al. Ledipasvir\/sofosbuvir is effective as sole treatment of porphyria cutanea tarda with chronic hepatitis C. Dig Dis Sci. 2023;68(6):2738-2746. https:\/\/doi.org\/10.1007\/s10620-023-07859-8","DOI":"10.1007\/s10620-023-07859-8"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Sastre L, To-Figueras J, Lens S et al. Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals. Aliment Pharmacol Ther. 2020;51(10):968-973. https:\/\/doi.org\/10.1111\/apt.15703","DOI":"10.1111\/apt.15703"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"El-Serag HB, Christie IC, Puenpatom A et al. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019;49(11):1442-1447. https:\/\/doi.org\/10.1111\/apt.15240","DOI":"10.1111\/apt.15240"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:12:04Z","timestamp":1759327924000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V01250056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":5,"URL":"https:\/\/doi.org\/10.61409\/v01250056","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}